On September 10, HANSOH PHARMA fell 3.22% in regular trading, trading at HK$33.74/share, with turnover of HK$139 million. The stock has been in consecutive retreat since surging 16.01% on August 27 following a better-than-expected interim report.

The broader pharmaceutical sector remains under pressure, with peers CSPC Pharma down 2.47%, Hengrui Pharma down 2.87%, Sihuan Pharm down 4.52%, and Fosun Pharma down 3.24%. Elevated short-selling activity, with short volume recently accounting for approximately 36% of total turnover, has compounded selling pressure on the stock.

Fundamentally, the company reported H1 revenue of RMB 8.304 billion, up 11.71% year-over-year, and attributable profit of RMB 4.258 billion, up 35.82%, with innovative drug revenue reaching a record 85.4% of total sales. Multiple investment banks including Goldman Sachs, J.P. Morgan, and CLSA have raised target prices to a range of HK$43.7 to HK$52.7, maintaining bullish ratings. However, sector-wide weakness and technical profit-taking following the sharp post-results rally continue to weigh on the share price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)